Explore Business Standard
Abbott
Global healthcare company Abbott on Monday announced the launch of a dual-chamber leadless pacemaker system, which will help the heart beat properly without wires or surgical pockets used in traditional pacemakers. Pacemakers help keep the heart beating at a healthy pace, especially in the case of bradycardia, a condition where the heart beats too slowly. In a statement, Abbott said its implant-to-implant device technology enables wireless communication and synchronisation between two leadless pacemakers, which are smaller than an AAA battery. Until recently, leadless pacemakers could only support one chamber of the heart, because getting two separate devices to work together in sync was a major challenge. "As leadless pacing technology has evolved, we've built upon our AVEIR VR single-chamber platform to expand the benefits of leadless pacing to far more people and provide additional treatment options to patients," said Ajay Singh Chauhan, General Manager for Abbott's cardiac rhyt
The DCGI has cautioned against the consumption of Abbott's antacid Digene gel citing safety concerns, even as the US-based drugmaker recalled several batches of the medicine manufactured at its Goa facility. According to a letter by the Drugs Controller General of India (DCGI), it was reported on August 9 that a bottle of Digene Gel (mint flavour), batch no 51030307, used by customers was of regular taste (sweet) and light pink in colour whereas another bottle of the same batch was of white colour with bitter taste and pungent odour as per a complaint. "Accordingly, M/s Abbott India Limited, Verna Industrial Estate, Salcette, Goa- vide letter dated August 11, 2023, informed DCGI office for voluntary recall of impugned product Digene Mint flavour batch no 51030307 and Digene Gel orange having batch no 50035107, 50035207, 50035307, 50035407 and voluntary stopped production of all variants of Digene Gel manufactured at their Goa facility," the DCGI letter stated. Further, Abbott India